Ramakrishna Homeo Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
- Paid Up Capital ₹ 9.97 M
- Company Age 33 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 1.40 Cr
- Revenue Growth 53.51%
- Profit Growth -361.63%
- Ebitda -364.59%
- Net Worth -277.21%
- Total Assets -80.98%
About Ramakrishna Homeo Pharmaceuticals
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24239TG1991PTC013374
-
Company No.
013374
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
31 Oct 1991
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Ramakrishna Homeo Pharmaceuticals?
Board Members (2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Naveen Nyapati
![]() |
Director | 20-Jul-2012 | Current |
Nyapathi Meghana
![]() |
Director | 25-Nov-2019 | Current |
Financial Performance of Ramakrishna Homeo Pharmaceuticals.
Ramakrishna Homeo Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 53.51% increase. The company also saw a substantial fall in profitability, with a 361.63% decrease in profit. The company's net worth observed a substantial decline by a decrease of 277.21%.
![Graph illustrating revenue growth over time](/Images/financial/revenue-growth.webp)
![Graph showing profit and loss trends over time](/Images/financial/profit-loss.webp)
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
|
||||||
Revenue from Operations |
|
||||||
Total Assets |
|
||||||
Profit or Loss |
|
||||||
Net Worth |
|
||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Ramakrishna Homeo Pharmaceuticals?
In 2023, Ramakrishna Homeo Pharmaceuticals had a promoter holding of 64.43% and a public holding of 35.57%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
![Shareholding Indicator graph](/Images/tcc-login/Shareholding-Indiacator-1200.webp)
Charges (Loans)
₹0
₹1.40 Cr
Charges Breakdown by Lending Institutions
- State Bank Of India : 1.40 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
27 Nov 1998 | State Bank Of India | ₹1.40 Cr | Satisfied |
How Many Employees Work at Ramakrishna Homeo Pharmaceuticals?
Unlock and access historical data on people associated with Ramakrishna Homeo Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
![Graph showing employee growth trends](/Images/tcc-login/Employee-Graph.webp)
Deals i
![Graph showing company valuation over time](/Images/tcc-login/Valuation-Graph-small.webp)
Gain comprehensive insights into the Deals and Valuation data of Ramakrishna Homeo Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ramakrishna Homeo Pharmaceuticals's trajectory.
Rating
![Graph displaying rating trends over time](/Images/tcc-login/Rating-Graph-small.webp)
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
![Alert Indicator](/Images/tcc-login/Alert-Indicator-small.webp)
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.